[moc::"[[]]"]
>[!title]
> RTOG 0227 [Glass JCO '16](http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8634): Phase I-II

>[!intervention]
> R-MTX/TMZ x5c→ WBRT 36/30 BID (1.2 Gy)→ TMZ.

# Study
## Phase I
- 13 pts with an increasing dose of TMZ (100/150/200)
## Phase II
- 53 pts
- MFU 3.6y
## Treatment
- Ritux 375, MTX 3.5 q2w x5c. TMZ w4, w8, then 200 for nearly 1y

# Results
## Response
- 51% CR, 34% PR

## Survival
- 2y OS 81%. 2y PFS 64%.
	- _much better than [[RTOG 9310 (MPV + WBRT 45 + MPV)#Survival|9310]]_

## Toxicity
- G3+ 66% before WBRT, G3+ after WBRT attributable to chemotherapy 45%. 
- Cognitive function and QoL improved or stabilized after RT. 
- Improved MMSE at 3y more pronounced in pts ≥ 60y.

>[!summary]
> Recall: CR after 5c / 7c of R-MPV of 50 → 80% [[MSK (R-MPV + WBRT 23.6 + Ara-C)#2013 Results]]. This study demonstrated 50% CR.
>^summary
